Research analysts at JPMorgan Chase & Co. initiated coverage on shares of Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report) in a report issued on Thursday, MarketBeat Ratings reports. The firm set an "overweight" rating on the stock.
Ascentage Pharma Group International Trading Up 0.2 %
Shares of NASDAQ:AAPG traded up $0.05 during trading on Thursday, reaching $21.70. 15,975 shares of the company traded hands, compared to its average volume of 84,257. Ascentage Pharma Group International has a 52 week low of $16.50 and a 52 week high of $22.43.
About Ascentage Pharma Group International
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Read More
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
